Henry Schein (NASDAQ:HSIC) Shares Gap Down – What’s Next?

Henry Schein, Inc. (NASDAQ:HSIC) shares gapped down prior to trading on Thursday. The stock had previously closed at $83.66, but opened at $79.95. Henry Schein shares last traded at $82.6010, with a volume of 366,651 shares traded.

Analyst Upgrades and Downgrades

HSIC has been the subject of several research analyst reports. Weiss Ratings upgraded shares of Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, August 21st. Stifel Nicolaus set a $95.00 target price on Henry Schein in a research report on Wednesday, August 5th. BTIG Research upped their price target on Henry Schein from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Barrington Research set a $104.00 price target on Henry Schein in a report on Wednesday, August 5th. Finally, Piper Sandler lifted their price objective on Henry Schein from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Nine investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $92.93.

Henry Schein Stock Down 0.8%

The business’s fifty day simple moving average is $87.73 and its 200 day simple moving average is $81.66. The stock has a market cap of $9.25 billion, a price-to-earnings ratio of 24.12, a price-to-earnings-growth ratio of 1.50 and a beta of 0.84. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The company had revenue of $3.46 billion for the quarter, compared to the consensus estimate of $3.37 billion. During the same quarter in the prior year, the business posted $1.10 EPS. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Equities analysts forecast that Henry Schein, Inc. will post 5.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HSIC. Southpoint Capital Advisors LP boosted its holdings in shares of Henry Schein by 28.0% during the 1st quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after buying an additional 700,000 shares during the period. Bank of New York Mellon Corp bought a new stake in Henry Schein in the 2nd quarter valued at $42,261,000. Staley Capital Advisers Inc. grew its holdings in Henry Schein by 12,115.2% in the 1st quarter. Staley Capital Advisers Inc. now owns 450,740 shares of the company’s stock valued at $33,220,000 after buying an additional 447,050 shares in the last quarter. Defilade Capital Management L.P. grew its holdings in Henry Schein by 94.8% in the 1st quarter. Defilade Capital Management L.P. now owns 624,037 shares of the company’s stock valued at $45,992,000 after buying an additional 303,615 shares in the last quarter. Finally, James J. Burns & Company LLC increased its position in Henry Schein by 1,293.7% during the 1st quarter. James J. Burns & Company LLC now owns 153,777 shares of the company’s stock worth $11,333,000 after buying an additional 142,743 shares during the period. Institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of health care products and services serving dental and medical professionals, laboratories, health care institutions and veterinary practices. The company operates primarily as a distributor, helping customers obtain medical, dental and veterinary supplies, equipment, pharmaceuticals and related products.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support practice management, clinical workflows, procurement, compliance and business operations.